Vanguard Capital Management
UTMD icon

Vanguard Capital Management’s Utah Medical Products UTMD Stock Holding History

Vanguard Capital Management’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.28M Sell
134,535
-4,025
-3% -$268K ﹤0.01% 2858
2026
Q1 		$8.59M Buy
+138,560
New +$8.73M ﹤0.01% 2814

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's UTMD Position: Q2 2026 in Review

Vanguard Capital Management reduced its Utah Medical Products (UTMD) stake by 2.9% in Q2 2026, selling an estimated $268K and leaving 134,535 shares worth $9.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2858.

Vanguard Capital Management first reported a position in UTMD in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Vanguard Capital Management held 134,535 shares of Utah Medical Products worth $9.28M as of Q2 2026.
  • Vanguard Capital Management sold 4,025 Utah Medical Products shares in Q2 2026, an estimated $268K.
  • Utah Medical Products made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2858 holding.
  • Vanguard Capital Management first reported a position in Utah Medical Products in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.